Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg - capsule - excipient ingredients: stearic acid; gelatin; maize starch; titanium dioxide; iron oxide yellow; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg - capsule - excipient ingredients: stearic acid; titanium dioxide; iron oxide yellow; maize starch; gelatin; microcrystalline cellulose; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg - capsule - excipient ingredients: stearic acid; maize starch; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg - capsule - excipient ingredients: maize starch; titanium dioxide; stearic acid; gelatin; iron oxide red; iron oxide yellow; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 7.2 mg - capsule - excipient ingredients: maize starch; microcrystalline cellulose; iron oxide yellow; titanium dioxide; gelatin; iron oxide red; stearic acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg - capsule - excipient ingredients: microcrystalline cellulose; maize starch; iron oxide red; iron oxide yellow; gelatin; titanium dioxide; stearic acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 7.2 mg - capsule - excipient ingredients: iron oxide yellow; stearic acid; maize starch; gelatin; microcrystalline cellulose; titanium dioxide; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg - capsule - excipient ingredients: stearic acid; microcrystalline cellulose; gelatin; maize starch; titanium dioxide; iron oxide red; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg - capsule - excipient ingredients: maize starch; stearic acid; gelatin; iron oxide yellow; titanium dioxide; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Canada - English - Health Canada

generic medical partners inc - rivastigmine (rivastigmine hydrogen tartrate) - capsule - 1.5mg - rivastigmine (rivastigmine hydrogen tartrate) 1.5mg - parasympathomemetic (cholinergic) agents